In the latest session, Viracta Therapeutics Inc (NASDAQ: VIRX) closed at $1.02 down -5.56% from its previous closing price of $1.08. In other words, the price has decreased by -$0.0600 from its previous closing price. On the day, 59259 shares were traded. VIRX stock price reached its highest trading level at $1.0800 during the session, while it also had its lowest trading level at $0.9800.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
For a deeper understanding of Viracta Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.43 and its Current Ratio is at 1.43. In the meantime, Its Debt-to-Equity ratio is 1.40 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, RBC Capital Mkts on February 01, 2022, initiated with a Outperform rating and assigned the stock a target price of $10.
On May 03, 2021, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $35.
On April 26, 2021, SVB Leerink started tracking the stock assigning a Outperform rating and target price of $18.SVB Leerink initiated its Outperform rating on April 26, 2021, with a $18 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Feb 27 ’24 when Chevallard Daniel R. sold 3,405 shares for $0.73 per share. The transaction valued at 2,493 led to the insider holds 102,306 shares of the business.
Rothera Mark bought 47,906 shares of VIRX for $23,627 on Dec 01 ’23. The President and CEO now owns 100,000 shares after completing the transaction at $0.49 per share. On Nov 30 ’23, another insider, Rothera Mark, who serves as the President and CEO of the company, bought 52,094 shares for $0.49 each. As a result, the insider paid 25,734 and bolstered with 52,094 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VIRX now has a Market Capitalization of 42.61M and an Enterprise Value of 19.93M.
Stock Price History:
Over the past 52 weeks, VIRX has reached a high of $2.38, while it has fallen to a 52-week low of $0.43. The 50-Day Moving Average of the stock is 0.7526, while the 200-Day Moving Average is calculated to be 0.9452.
Shares Statistics:
For the past three months, VIRX has traded an average of 99.67K shares per day and 72.87k over the past ten days. A total of 39.09M shares are outstanding, with a floating share count of 27.29M. Insiders hold about 30.50% of the company’s shares, while institutions hold 24.61% stake in the company. Shares short for VIRX as of Mar 15, 2024 were 634.26k with a Short Ratio of 6.36, compared to 678.82k on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.62% and a Short% of Float of 2.05%.
Earnings Estimates
There are 3 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.36 for the current quarter, with a high estimate of -$0.34 and a low estimate of -$0.37, while EPS last year was -$0.32. The consensus estimate for the next quarter is -$0.36, with high estimates of -$0.34 and low estimates of -$0.39.
Analysts are recommending an EPS of between -$1.15 and -$1.42 for the fiscal current year, implying an average EPS of -$1.31. EPS for the following year is -$1.21, with 2 analysts recommending between -$1.09 and -$1.34.
